Teladoc Health (TDOC) | Financial Analysis & Statements
Teladoc Health Inc. Small-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
642.3M
Gross Profit
445.2M
69.32%
Operating Income
-27.0M
-4.20%
Net Income
-25.1M
-3.91%
EPS (Diluted)
$-0.14
Balance Sheet Metrics
Total Assets
2.9B
Total Liabilities
1.5B
Shareholders Equity
1.4B
Debt to Equity
1.06
Cash Flow Metrics
Operating Cash Flow
81.9M
Free Cash Flow
53.4M
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Teladoc Health Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 2.5B | 2.6B | 2.6B | 2.4B | 2.0B |
| Cost of Goods Sold | 771.6M | 751.3M | 760.0M | 744.0M | 650.3M |
| Gross Profit | 1.8B | 1.8B | 1.8B | 1.7B | 1.4B |
| Gross Margin % | 69.5% | 70.8% | 70.8% | 69.1% | 68.0% |
| Operating Expenses | |||||
| Research & Development | 277.9M | 307.3M | 348.5M | 333.6M | 311.9M |
| Selling, General & Administrative | 1.3B | 1.3B | 1.4B | 1.3B | 1.1B |
| Other Operating Expenses | - | - | - | - | - |
| Total Operating Expenses | 1.6B | 1.7B | 1.7B | 1.6B | 1.4B |
| Operating Income | -163.4M | -208.8M | -210.5M | -227.4M | -239.0M |
| Operating Margin % | -6.5% | -8.1% | -8.1% | -9.4% | -11.8% |
| Non-Operating Items | |||||
| Interest Income | 36.8M | 57.1M | 46.8M | 12.7M | 776.0K |
| Interest Expense | 19.7M | 23.8M | 22.3M | 21.9M | 81.1M |
| Other Non-Operating Income | -89.2M | -818.1M | -33.6M | -13.4B | -65.3M |
| Pre-tax Income | -235.5M | -993.7M | -219.6M | -13.7B | -384.7M |
| Income Tax | -35.2M | 7.6M | 760.0K | -3.8M | 44.1M |
| Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Income | -200.3M | -1.0B | -220.4M | -13.7B | -428.8M |
| Net Margin % | -7.9% | -39.0% | -8.5% | -567.5% | -21.1% |
| Key Metrics | |||||
| EBITDA | 260.2M | 225.1M | 192.0M | 55.1M | -13.5M |
| EPS (Basic) | - | $-5.87 | $-1.34 | $-84.60 | $-2.73 |
| EPS (Diluted) | - | $-5.87 | $-1.34 | $-84.60 | $-2.73 |
| Basic Shares Outstanding | - | 170564088 | 162169564 | 161457123 | 156939349 |
| Diluted Shares Outstanding | - | 170564088 | 162169564 | 161457123 | 156939349 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Teladoc Health Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 781.1M | 1.3B | 1.1B | 918.2M | 893.5M |
| Short-term Investments | - | - | - | 0 | 2.5M |
| Accounts Receivable | 192.8M | 214.1M | 217.4M | 210.6M | 169.0M |
| Inventory | 38.2M | 38.1M | 29.5M | 56.3M | 73.1M |
| Other Current Assets | 2.1M | 2.8M | 7.4M | 12.1M | 5.7M |
| Total Current Assets | 1.1B | 1.7B | 1.5B | 1.3B | 1.2B |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 42.0M | 43.0M | 55.2M | 54.5M | 57.8M |
| Goodwill | 1.9B | 2.0B | 3.8B | 4.0B | 30.9B |
| Intangible Assets | 1.3B | 1.4B | 1.7B | 1.8B | 1.9B |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 105.8M | 81.5M | 80.3M | 48.5M | 20.7M |
| Total Non-Current Assets | 1.7B | 1.9B | 2.9B | 3.0B | 16.5B |
| Total Assets | 2.9B | 3.5B | 4.4B | 4.3B | 17.7B |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 48.0M | 33.1M | 43.6M | 47.7M | 47.3M |
| Short-term Debt | 11.0M | 561.1M | 10.8M | 13.6M | 12.7M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 27.4M | 32.5M | 37.5M | 44.9M | 40.3M |
| Total Current Liabilities | 404.7M | 941.5M | 420.6M | 399.8M | 331.0M |
| Non-Current Liabilities | |||||
| Long-term Debt | 1.0B | 1.0B | 1.6B | 1.6B | 1.3B |
| Deferred Tax Liabilities | 28.9M | 49.9M | 49.5M | 50.9M | 75.8M |
| Other Non-Current Liabilities | 643.0K | 720.0K | 1.1M | 1.6M | 10.8M |
| Total Non-Current Liabilities | 1.1B | 1.1B | 1.6B | 1.6B | 1.4B |
| Total Liabilities | 1.5B | 2.0B | 2.1B | 2.0B | 1.7B |
| Equity | |||||
| Common Stock | 178.0K | 173.0K | 167.0K | 163.0K | 160.0K |
| Retained Earnings | -16.4B | -16.2B | -15.2B | -15.0B | -1.4B |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 1.4B | 1.5B | 2.3B | 2.3B | 16.0B |
| Key Metrics | |||||
| Total Debt | 1.0B | 1.6B | 1.6B | 1.6B | 1.3B |
| Working Capital | 714.4M | 722.4M | 1.1B | 915.6M | 894.4M |
Balance Sheet Composition
Teladoc Health Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -200.3M | -1.0B | -220.4M | -13.7B | -428.8M |
| Depreciation & Amortization | 376.4M | 382.8M | 351.3M | 270.6M | 219.6M |
| Stock-Based Compensation | 80.4M | 146.0M | 201.6M | 217.9M | 302.6M |
| Working Capital Changes | 4.1M | -51.2M | -29.1M | -56.2M | -26.4M |
| Operating Cash Flow | 225.6M | -515.0M | 304.6M | -13.2B | 166.2M |
| Investing Activities | |||||
| Capital Expenditures | - | - | - | - | - |
| Acquisitions | -81.9M | - | 0 | 0 | -78.7M |
| Investment Purchases | -27.9M | - | - | - | - |
| Investment Sales | 740.0K | 0 | 0 | 2.5M | 60.9M |
| Investing Cash Flow | -109.0M | 0 | 1.0K | 5.0M | -9.0M |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | - | - | - | 0 | 0 |
| Debt Repayment | -550.6M | - | - | 0 | -139.0K |
| Financing Cash Flow | -554.7M | -2.0K | -278.0K | -5.9M | -1.8M |
| Free Cash Flow | 137.3M | 169.6M | 193.7M | 16.5M | 130.1M |
| Net Change in Cash | -438.1M | -515.0M | 304.3M | -13.2B | 155.4M |
Cash Flow Trend
Teladoc Health Key Financial Ratios
Valuation Ratios
Forward P/E
-6.16
Price to Book
0.74
Price to Sales
0.41
PEG Ratio
-6.16
Profitability Ratios
Profit Margin
-7.92%
Operating Margin
-4.20%
Return on Equity
-13.93%
Return on Assets
-3.20%
Financial Health
Current Ratio
2.76
Debt to Equity
75.06
Beta
2.08
Per Share Data
EPS (TTM)
$-34.20
Book Value per Share
$7.77
Revenue per Share
$14.36
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| TDOC | 1.0B | - | 0.74 | -13.93% | -7.92% | 75.06 |
| Ge Healthcare | 31.9B | 15.92 | 3.18 | 22.38% | 10.10% | 98.72 |
| Veeva Systems | 26.5B | 29.57 | 3.66 | 13.93% | 28.45% | 1.33 |
| Omnicell | 1.7B | 918.75 | 1.34 | 0.17% | 0.17% | 16.59 |
| Certara | 969.0M | 105.00 | 0.95 | -0.15% | -0.38% | 28.96 |
| Schrodinger | 870.4M | 44.39 | 2.39 | -26.29% | -40.36% | 30.03 |
Financial data is updated regularly. All figures are in the company's reporting currency.






